AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS:A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 µm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn't show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME.
RCT Entities:
AIM: To compare the effectiveness of intravitreal bevacizumab and subthreshold macular photocoagulation (SMP), for the treatment of non-center involved diabetic macular edema (non-CI DME). METHODS: Prospective, randomized, controlled clinical study included patients with type 2 diabetes, non-CI DME and best-corrected visual acuity (BCVA) of 0.30 logMAR or better. Each eye was randomized into three groups: group 1, monthly intravitreal bevacizumab; group 2, single SMP; group 3, single SMP and monthly bevacizumab. Main outcome measures were BCVA, and macular thickness measured with optical coherence tomography as macular central subfield thickness (CST), macular area of greater thickness (MAGT) and total macular volume (TMV). Results were analyzed after 3mo. RESULTS: A total of 32 eyes were included. Group 3 improved in BCVA (0.19±0.16 to 0.12±0.14 logMAR; P=0.041) and in TMV (7.90±0.57 to 7.65±0.73 mm3; P=0.025). Group 1 improved in MAGT (325±26.26 to 298.20±44.85 µm; P=0.022) and TMV (7.79±0.57 to 7.50±0.56 mm3, P=0.047). Group 2 didn't show significant improvement of any variable. CONCLUSION: The loading phase of bevacizumab as monotherapy or combined with SMP is superior to SMP as monotherapy in providing short-term visual and anatomical improvement in non-CI DME.
Authors: F Bandello; J Cunha-Vaz; N V Chong; G E Lang; P Massin; P Mitchell; M Porta; C Prünte; R Schlingemann; U Schmidt-Erfurth Journal: Eye (Lond) Date: 2012-01-13 Impact factor: 3.775
Authors: Michael J Elman; Allison Ayala; Neil M Bressler; David Browning; Christina J Flaxel; Adam R Glassman; Lee M Jampol; Thomas W Stone Journal: Ophthalmology Date: 2014-10-28 Impact factor: 12.079
Authors: Quan Dong Nguyen; Syed Mahmood Shah; Afsheen A Khwaja; Roomasa Channa; Elham Hatef; Diana V Do; David Boyer; Jeffery S Heier; Prema Abraham; Allen B Thach; Eugene S Lit; Bradley S Foster; Erik Kruger; Pravin Dugel; Thomas Chang; Arup Das; Thomas A Ciulla; John S Pollack; Jennifer I Lim; Dean Eliott; Dean Eliot; Peter A Campochiaro Journal: Ophthalmology Date: 2010-09-19 Impact factor: 12.079
Authors: Ranjan Rajendram; Samantha Fraser-Bell; Andrew Kaines; Michel Michaelides; Robin D Hamilton; Simona Degli Esposti; Tunde Peto; Catherine Egan; Catey Bunce; Richard David Leslie; Philip G Hykin Journal: Arch Ophthalmol Date: 2012-08
Authors: Ingrid U Scott; Ronald P Danis; Susan B Bressler; Neil M Bressler; David J Browning; Haijing Qin Journal: Retina Date: 2009-05 Impact factor: 4.256
Authors: Donald S Fong; Samara F Strauber; Lloyd Paul Aiello; Roy W Beck; David G Callanan; Ronald P Danis; Matthew D Davis; Stephen S Feman; Frederick Ferris; Scott M Friedman; Charles A Garcia; Adam R Glassman; Dennis P Han; Darma Le; Craig Kollman; Andreas K Lauer; Franco M Recchia; Sharon D Solomon Journal: Arch Ophthalmol Date: 2007-04
Authors: Philip Hooper; Marie-Carole Boucher; Kevin Colleaux; Alan Cruess; Mark Greve; Wai-Ching Lam; Stanley Shortt; Eric Tourville Journal: Ophthalmologica Date: 2013-11-12 Impact factor: 3.250
Authors: Sharon D Solomon; Emily Chew; Elia J Duh; Lucia Sobrin; Jennifer K Sun; Brian L VanderBeek; Charles C Wykoff; Thomas W Gardner Journal: Diabetes Care Date: 2017-03 Impact factor: 19.112